MX2015009696A - Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. - Google Patents

Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.

Info

Publication number
MX2015009696A
MX2015009696A MX2015009696A MX2015009696A MX2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A MX 2015009696 A MX2015009696 A MX 2015009696A
Authority
MX
Mexico
Prior art keywords
heparinoid
acute
buffer
acting anesthetic
compositions
Prior art date
Application number
MX2015009696A
Other languages
English (en)
Inventor
C Lowell Parsons
Original Assignee
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urigen Pharmaceuticals Inc filed Critical Urigen Pharmaceuticals Inc
Publication of MX2015009696A publication Critical patent/MX2015009696A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos mejorados para preparar composiciones incluyen un heparinoide, un anestésico de acción aguda y un regulador de pH; estos métodos resultan en composiciones en las que el heparinoide y el anestésico de acción aguda son por lo menos 90% estables durante un año; las composiciones preparadas mediante estos métodos y que tienen tales propiedades de estabilidad mejorada también se describen, así como métodos de uso de estas composiciones para tratar, aliviar o evitar trastornos del tracto urinario inferior tal como la cistitis.
MX2015009696A 2013-01-28 2014-01-28 Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. MX2015009696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757592P 2013-01-28 2013-01-28
PCT/US2014/013352 WO2014171986A1 (en) 2013-01-28 2014-01-28 Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer

Publications (1)

Publication Number Publication Date
MX2015009696A true MX2015009696A (es) 2016-03-31

Family

ID=51731742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009696A MX2015009696A (es) 2013-01-28 2014-01-28 Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.

Country Status (13)

Country Link
US (1) US20150359816A1 (es)
EP (1) EP2948154A4 (es)
JP (2) JP2016517390A (es)
KR (1) KR20160008496A (es)
CN (1) CN105263503A (es)
AU (2) AU2014254472A1 (es)
BR (1) BR112015018047A8 (es)
CA (1) CA2899636C (es)
IL (1) IL240194B (es)
MX (1) MX2015009696A (es)
SG (1) SG11201505853RA (es)
WO (1) WO2014171986A1 (es)
ZA (1) ZA201505814B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117847B2 (en) 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
EP3609483A4 (en) * 2017-04-12 2021-01-20 Urigen Pharmaceuticals, Inc. ITEM OF MANUFACTURING CONSISTING OF LOCAL ANESTHETICS, BUFFER AND GLYCOSAMINOGLYCANE IN A SYRINGE OF IMPROVED STABILITY
ES2775673T3 (es) * 2017-05-12 2020-07-27 Farco Gmbh Composición para el tratamiento de enfermedades inflamatorias del tracto urogenital que contiene sulfato de condonita (4,5 mg/ml), ácido hialurónico (16 mg/ml) y tampón de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para tratar la cistitis
EP3415163B1 (de) * 2017-06-13 2023-02-22 Farco-Pharma GmbH Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
ES2968164T3 (es) * 2019-04-26 2024-05-08 Tcm Biotech Int Corp Composición farmacéutica para la prevención de infección urinaria recurrente
TW202105790A (zh) * 2019-05-17 2021-02-01 日商半導體能源研究所股份有限公司 發光元件、發光裝置、電子機器及照明裝置
EP3998932A4 (en) * 2019-07-18 2023-08-16 C. Lowell Parsons ALKALINIZATION OF THE URINARY BLADDER WALL BEFORE TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALIZED LIDOCAINE TO ENHANCE SYMPTOMS RELIEF OF PAIN BLADDER
CN115814099B (zh) * 2022-12-19 2024-04-26 成都蓉生药业有限责任公司 一种人凝血因子ix的干热处理稳定剂及其制剂与制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603695A (en) * 1995-06-07 1997-02-18 Erickson; Kim Device for alkalizing local anesthetic injection medication
DK1708722T3 (da) * 2004-01-28 2014-08-25 Univ California Ny interstitiel terapi til øjeblikkelig symptomlindring og kronisk terapived interstitiel cystit
AU2006204769A1 (en) * 2005-01-14 2006-07-20 Urigen, Inc. Kits and improved compositions for treating lower urinary tract
WO2007073397A1 (en) * 2005-12-19 2007-06-28 Urigen, Inc. Kits and improved compositions for treating lower urinary tract discorders
US8450475B2 (en) * 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
ES2634505T3 (es) * 2009-08-13 2017-09-28 Lubris Llc Tratamiento de PRG4 para la cistitis intersticial
EA201391014A1 (ru) * 2011-01-06 2014-01-30 С. Лоуэлл Парсонс Способ производства композиции, содержащей местный анестетик, гепариноид и буфер
US9486747B2 (en) * 2014-08-12 2016-11-08 The Curators Of The University Of Missouri Nanocomposite membranes with advanced antifouling properties under visible light irradiation

Also Published As

Publication number Publication date
BR112015018047A8 (pt) 2019-11-05
BR112015018047A2 (pt) 2017-07-18
AU2018247284A1 (en) 2018-11-01
JP2019006783A (ja) 2019-01-17
JP2016517390A (ja) 2016-06-16
IL240194A0 (en) 2015-09-24
EP2948154A1 (en) 2015-12-02
CN105263503A (zh) 2016-01-20
EP2948154A4 (en) 2016-09-14
AU2014254472A1 (en) 2015-08-20
ZA201505814B (en) 2016-11-30
KR20160008496A (ko) 2016-01-22
SG11201505853RA (en) 2015-08-28
WO2014171986A1 (en) 2014-10-23
CA2899636A1 (en) 2014-10-23
CA2899636C (en) 2021-05-25
IL240194B (en) 2021-12-01
US20150359816A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
IN2015DN01156A (es)
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
PH12016502066A1 (en) Methods of treating bladder cancer
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016002794A (es) Compuestos antiproliferativos.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX339201B (es) Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
SG10201810928SA (en) Novel antitumoral use of cabazitaxel
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2016008226A (es) Metodos para el cuidado oral prebiotico usando un sacarido.
MX2016009241A (es) Metodos para reducir el mal olor y las bacterias.
MY191932A (en) Chitosan-derived compositions